


PATENT
ATTORNEY DOCKET NO. 50010/017003

Certificate of Mailing	
Date of Deposit <u>April 27, 2001</u>	Label Number: <u>EL509219123US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Guy Beardsley</u> Printed name of person mailing correspondence	 Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Douglas A. Treco et al. Art Unit: Not Yet Assigned
Serial No.: Not Yet Assigned Examiner: Not Yet Assigned
Filed: April 27, 2001 Customer No.: 21559
Title: Genomic Sequences for Protein Production and Delivery

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-captioned patent application, which is being filed herewith, kindly amend the application as follows.

In the Specification:

At page 1, after line 7, insert the following new paragraph:

This application also claims the benefit of U.S. Patent Application Serial No. 09/305,384, filed May 5, 1999, which is also herein incorporated by reference.

Insert the enclosed Sequence Listing at the end of the Specification, after the Combined Declaration and Power of Attorney.

09/305,384

In the Claims:

Please cancel claims 1-34 and add the following new claims 35-50.

35. (New) A method of delivering G-CSF to an animal, said method comprising providing a homologously recombinant cell that is stably transfected with a DNA construct that comprises (i) a targeting sequence comprising 20 contiguous nucleotides of SEQ ID NO:5, and (ii) a transcriptional regulatory sequence, wherein the DNA construct has undergone homologous recombination with genomic DNA upstream of the ATG initiation codon of an endogenous G-CSF coding sequence; and

implanting the cell in the animal, wherein the cell secretes G-CSF.

36. (New) The method of claim 35, wherein the DNA construct further comprises an exon and a splice donor site.

37. (New) The method of claim 36, wherein the DNA construct further comprises, downstream from the splice donor site, and intron and a splice acceptor site.

38. (New) The method of claim 37, wherein the DNA construct further comprises a selectable marker gene.

39. (New) The method of claim 35, wherein the targeting sequence comprises 50

contiguous nucleotides from SEQ ID NO:5.

40. (New) The method of claim 39, wherein the targeting sequence comprises 100 contiguous nucleotides from SEQ ID NO:5.

41. (New) The method of claim 40, wherein the targeting sequence comprises 200 contiguous nucleotides from SEQ ID NO:5.

42. (New) The method of claim 41, wherein the targeting sequence comprises 500 contiguous nucleotides from SEQ ID NO:5.

43. (New) The method of claim 35, wherein the targeting sequence comprises a sequence of at least 100 nucleotides that hybridizes under highly stringent conditions with SEQ ID NO:5 or the complement thereof.

44. (New) The method of claim 43, wherein the targeting sequence is at least 400 nucleotides in length.

45. (New) The method of claim 43, wherein the targeting sequence is at least 1,000 nucleotides in length.

46. (New) The method of claim 35, wherein the targeting sequence comprises a sequence that is at least 100 nucleotides in length and shares at least 80% sequence identity with a fragment of SEQ ID NO:5 having the same length as the sequence.

47. (New) The method of claim 46, wherein the targeting sequence is at least 200 nucleotides in length.

48. (New) The method of claim 47, wherein the targeting sequence is at least 400 nucleotides in length.

49. (New) The method of claim 48, wherein the targeting sequence is at least 1,000 nucleotides in length.

50. (New) The method of claim 35, wherein the animal is a human.

REMARKS

The amendments set forth above are being made to add priority information to the specification, to cancel claims 1-34, and to add new claims 35-50, which correspond to original claims 27-30 and several original dependent claims. No new matter is added by the present amendments.

Although no charges are believed to be due, if there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: April 27, 2001

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045
50010.017003 preliminary amendment.wpd



21559

PATENT TRADEMARK OFFICE